Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNFAIP3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFAIP3 Recombinant Protein (OTU Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic and binding assays. |
View TNFAIP3 Products |
| Gene Delivery | TNFAIP3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View TNFAIP3 Products |
| Benchmark Ab | Anti-TNFAIP3 Recombinant Antibody High-affinity positive control for Western Blot, IP, and intracellular flow cytometry. |
View TNFAIP3 Products |
| Validator | TNFAIP3 siRNA Set Target-specific knockdown verification in human primary cells and cell lines. |
View TNFAIP3 Products |
| Related Target A | RIPK1 Direct substrate of TNFAIP3; key node in necroptosis and NF-kB signaling pathways. |
View RIPK1 Products |
| Related Target B | IKBKG (NEMO) Downstream regulator in the NF-kB pathway interacting directly with TNFAIP3 complexes. |
View IKBKG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual Enzymatic Activity Verification (DUB vs. E3 Ligase) | Domain-specific recombinant proteins (OTU domain and Zinc Finger domains) expressed with precise boundary designs. |
| Intracellular Target Access & Validation | High-titer Lentiviral particles for stable cell line generation to monitor NF-kB reporter activity. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and validated siRNA knockdowns included. |
| False Positives in Screening | High-purity (>95% by SDS-PAGE) recombinant proteins ensuring low background in biochemical assays. |
Live TNFAIP3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFAIP3 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted modulation of the ubiquitin-editing machinery. As first-generation small molecule inhibitors of the OTU domain reach preclinical validation, the next wave of R&D is targeting the tissue-specific delivery of TNFAIP3-activating gene therapies and mRNA therapeutics to treat inflammatory bowel disease (IBD) and lupus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Incyte, Novartis, Academic Consortia | Oncology (Immunotherapy enhancement) | OTU Domain DUB Assay (Need high-purity recombinant OTU domain protein) |
| Gene Therapy / mRNA | Moderna, Pfizer | Inflammatory Bowel Disease (IBD), HA20 | Overexpression Validation (Need Lentivirus for stable cell line generation) |
| PROTAC / Degraders | Arvinas, Kymera Therapeutics | Autoimmune Diseases, Lymphoma | Ubiquitination Assay (Need recombinant TNFAIP3 and substrate RIPK1) |